ICMR Guidelines for Management of Anti‑Tubercular Drug‑Induced Hepatotoxicity

Stopping Criteria for Hepatotoxic Drugs

• In patients with asymptomatic transaminase elevations ≥ 5 × upper‑limit‑of‑normal (ULN), stop rifampicin, isoniazid and pyrazinamide immediately. 1, 2
• In patients with hepatitis symptoms (fever, malaise, vomiting, nausea) and transaminase elevations ≥ 3 × ULN, stop all hepatotoxic anti‑TB drugs. 1, 2
• Any rise in bilirubin above the normal range mandates immediate discontinuation of rifampicin, isoniazid and pyrazinamide, irrespective of transaminase levels. 1, 2

Monitoring Protocol Based on Transaminase Levels

• AST/ALT < 2 × ULN – continue the full anti‑TB regimen at standard doses; repeat liver‑function tests (LFTs) after 2 weeks. If values fall, further testing is required only if symptoms develop; if repeat values rise > 2 × ULN, switch to weekly monitoring. 1
• AST/ALT 2–5 × ULN in asymptomatic patients – maintain full‑dose therapy; perform weekly LFTs for the first 2 weeks, then every 2 weeks until normalization. Counsel patients about hepatotoxicity symptoms and advise complete avoidance of alcohol. Exclude alternative causes (viral hepatitis, biliary disease, other hepatotoxic drugs). 1, 2
• AST/ALT > 5 × ULN or any bilirubin elevation – stop rifampicin, isoniazid and pyrazinamide immediately; continue ethambutol and, if renal function permits and the patient has active or severe TB, add streptomycin. In non‑ill patients with non‑infectious TB, defer treatment until LFTs normalize. Repeat LFTs within 2–3 days. 1, 2

Sequential Re‑introduction of Anti‑TB Drugs (after LFT Normalization)

• General principle – re‑introduce drugs one at a time with daily clinical and biochemical monitoring. 1

• Step 1 – Isoniazid

  • Start 50 mg once daily; if no reaction after 2–3 days, increase to 300 mg daily.
  • Maintain full dose for 2–3 days before adding the next drug; monitor LFTs daily. 1

• Step 2 – Rifampicin (after isoniazid tolerated)

  • Begin 75 mg once daily; raise to 300 mg after 2–3 days if tolerated.
  • Further increase to 450 mg (patient < 50 kg) or 600 mg (patient ≥ 50 kg) after another 2–3 days.
  • Continue full dose for 2–3 days before introducing pyrazinamide; daily LFT monitoring continues. 1

• Step 3 – Pyrazinamide (after rifampicin tolerated)

  • Initiate 250 mg once daily; increase to 1.0 g after 2–3 days.
  • Then raise to 1.5 g (patient < 50 kg) or 2.0 g (patient ≥ 50 kg) after an additional 2–3 days, with ongoing daily LFT checks. 1

• Recurrence of hepatotoxicity – if liver injury re‑appears during re‑introduction, permanently discontinue the offending drug and switch to an alternative regimen. 1

Alternative Regimens When Hepatotoxic Drugs Cannot Be Used

• If pyrazinamide is the offending agent – treat with rifampicin + isoniazid for a total of 9 months, adding ethambutol for the initial 2 months. 1
• If multiple hepatotoxic drugs cannot be re‑introduced – use ethambutol + streptomycin as the backbone, supplemented with a fluoroquinolone (levofloxacin or moxifloxacin), which does not add hepatotoxic risk. 1

Critical Pitfalls to Avoid

• Never continue therapy when bilirubin rises – any bilirubin elevation is an absolute indication to stop hepatotoxic anti‑TB drugs. 1, 2
• Never re‑introduce pyrazinamide if it was previously identified as the offending drug – doing so risks recurrence with poor prognosis. 1

All recommendations are derived from the ICMR (Indian Council of Medical Research) guidelines, supported by evidence cited from Thorax (1998) and the European Respiratory Journal (1999).

Management of Asymptomatic Transaminase Elevation During Anti-Tuberculosis Treatment

Assessment and Monitoring

• The American Thoracic Society recommends continuing all anti-tuberculosis medications without interruption and monitoring liver function tests weekly for two weeks, then biweekly, as the transaminases are below 5 times the upper limit of normal and bilirubin remains normal in this asymptomatic patient 3, 4
• Patients with AST/ALT between 2-5 times normal in asymptomatic patients should be monitored with liver function tests weekly for 2 weeks, then biweekly, until values normalize or stabilize, and continue all anti-tuberculosis medications at full doses during monitoring 3, 5

Criteria for Stopping Anti-Tuberculosis Drugs

• The Infectious Diseases Society of America recommends stopping rifampicin, isoniazid, and pyrazinamide immediately if ALT/AST rises to ≥5 times the upper limit of normal in asymptomatic patients, or if ALT/AST ≥3 times the upper limit of normal with symptoms, or if bilirubin rises above normal 3, 4, 5

Exclusion of Other Causes

• The Centers for Disease Control and Prevention recommends excluding other causes of enzyme elevation, such as viral hepatitis, biliary tract disease, alcohol consumption, and other hepatotoxic medications, before attributing enzyme elevation solely to anti-TB drugs 4, 5, 6

Management of Hepatotoxicity

• The World Health Organization recommends stopping rifampicin, isoniazid, and pyrazinamide immediately if AST/ALT reaches ≥5× ULN or bilirubin rises, and continuing ethambutol and streptomycin if patient has infectious TB or is acutely ill 3, 5

Management of Elevated AST During Anti‑Tuberculosis Therapy (cited)

Immediate Assessment of Elevated AST

• The 2003 ATS/CDC/IDSA guidelines recommend that when a patient on anti‑TB therapy shows an elevated AST, clinicians should promptly (1) assess for hepatitis symptoms (fever, malaise, nausea, vomiting, jaundice, abdominal pain) and (2) measure the exact AST level relative to the upper limit of normal (ULN). Evidence level: expert consensus 7, 8

Monitoring and Thresholds for Drug Modification

• The same 2003 ATS/CDC/IDSA guidelines advise excluding alternative causes of liver injury—viral hepatitis (A, B, C), biliary disease, alcohol use, or other hepatotoxic medications—when AST is 2–5 × ULN and the patient is asymptomatic. Evidence level: expert consensus 7, 8
• The guidelines also recommend screening for hepatitis B and C at baseline (or if not previously performed) in high‑risk groups such as injection‑drug users, persons born in Asia/Africa, and HIV‑positive individuals. Evidence level: expert consensus 9, 10
• According to the 2003 ATS/CDC/IDSA guidelines, if AST is ≥5 × ULN in an asymptomatic patient or ≥3 × ULN in a symptomatic patient, rifampicin, isoniazid, and pyrazinamide should be stopped immediately. Evidence level: expert consensus 7, 8
• The same guidelines state that ethambutol may be continued when the above hepatotoxic drugs are stopped. Evidence level: expert consensus 7, 8

Sequential Re‑introduction of Anti‑TB Drugs

• The 2003 ATS/CDC/IDSA guidelines outline a stepwise re‑introduction protocol once AST falls below 2 × ULN and symptoms improve: (1) re‑introduce isoniazid first, (2) add rifampicin next, and (3) finally add pyrazinamide, with daily clinical and biochemical monitoring after each step. Evidence level: expert consensus 7, 8

Baseline and Ongoing Liver Function Monitoring Recommendations

• The 2016 ATS/CDC/IDSA guidelines specify that baseline liver function tests are required only if any of the following are present: abnormal baseline LFTs, hepatotoxic symptoms, chronic alcohol consumption, concomitant hepatotoxic medications, existing viral hepatitis or liver disease, or HIV infection. Evidence level: moderate‑quality guideline 10
• The same 2016 guidelines recommend that routine monthly LFT monitoring is not indicated for patients without the above risk factors. Evidence level: moderate‑quality guideline 10

Risk Factors and Screening

• The 2003 ATS/CDC/IDSA guidelines identify hepatitis B or C co‑infection as a risk factor for anti‑TB drug‑induced hepatotoxicity. Evidence level: expert consensus 9

Evidence Base Summary

• The thresholds for AST elevation, drug‑stopping rules, and monitoring strategies are derived from the 2003 ATS/CDC/IDSA treatment guidelines and are reinforced by the 2016 ATS/CDC/IDSA clinical practice guidelines. Both sets of guidelines are based primarily on expert consensus and observational data rather than randomized trials. Evidence level: expert consensus 7, 8, 10